SG11201609382WA - Compositions and methods for stabilizing luminogenic substrates - Google Patents

Compositions and methods for stabilizing luminogenic substrates

Info

Publication number
SG11201609382WA
SG11201609382WA SG11201609382WA SG11201609382WA SG11201609382WA SG 11201609382W A SG11201609382W A SG 11201609382WA SG 11201609382W A SG11201609382W A SG 11201609382WA SG 11201609382W A SG11201609382W A SG 11201609382WA SG 11201609382W A SG11201609382W A SG 11201609382WA
Authority
SG
Singapore
Prior art keywords
stabilizing
compositions
methods
luminogenic substrates
luminogenic
Prior art date
Application number
SG11201609382WA
Other languages
English (en)
Inventor
Thomas Kirkland
Keith V Wood
Mary Hall
Marie Schwinn
Original Assignee
Promega Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Promega Corp filed Critical Promega Corp
Publication of SG11201609382WA publication Critical patent/SG11201609382WA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/061,2,4-Triazines
    • C07D253/0651,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/071,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D253/00Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/061,2,4-Triazines
    • C07D253/0651,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/071,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075Two hetero atoms, in positions 3 and 5
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00Luminescent, e.g. electroluminescent, chemiluminescent materials
    • C09K11/06Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/66Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10Non-macromolecular compounds
    • C09K2211/1003Carbocyclic compounds
    • C09K2211/1007Non-condensed systems
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09KMATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10Non-macromolecular compounds
    • C09K2211/1018Heterocyclic compounds
    • C09K2211/1025Heterocyclic compounds characterised by ligands
    • C09K2211/1044Heterocyclic compounds characterised by ligands containing two nitrogen atoms as heteroatoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Materials Engineering (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Electroluminescent Light Sources (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG11201609382WA 2014-05-23 2015-05-26 Compositions and methods for stabilizing luminogenic substrates SG11201609382WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462002363P 2014-05-23 2014-05-23
PCT/US2015/032439 WO2015179864A1 (en) 2014-05-23 2015-05-26 Compositions and methods for stabilizing luminogenic substrates

Publications (1)

Publication Number Publication Date
SG11201609382WA true SG11201609382WA (en) 2016-12-29

Family

ID=53434457

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201609382WA SG11201609382WA (en) 2014-05-23 2015-05-26 Compositions and methods for stabilizing luminogenic substrates

Country Status (10)

Country Link
US (1) US9676997B2 (enExample)
EP (1) EP3146066B1 (enExample)
JP (1) JP6641297B2 (enExample)
KR (1) KR102456212B1 (enExample)
CN (1) CN106661028B (enExample)
AU (1) AU2015263901B2 (enExample)
BR (1) BR112016027504B1 (enExample)
CA (1) CA2949447C (enExample)
SG (1) SG11201609382WA (enExample)
WO (1) WO2015179864A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3661932B1 (en) 2017-08-04 2021-10-06 Promega Corporation Compositions and methods for stabilizing benzothiazole luciferin analogs
US11534504B2 (en) 2018-10-03 2022-12-27 Promega Corporation Compositions and methods for stabilizing coelenterazine and analogs and derivatives thereof
CN111116594B (zh) * 2019-12-03 2021-05-28 山东大学 一种C-6位改造NanoLuc类型类似物及其制备方法与应用
WO2025242077A1 (zh) * 2024-05-21 2025-11-27 深圳琅技生命科技有限公司 用于稳定腔肠素及其类似物的组合物及方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2000622A1 (de) * 1970-01-08 1971-07-22 Agfa Gevaert Ag Verfahren zur Stabilisierung von Silberbildern
JP4639904B2 (ja) * 2005-03-30 2011-02-23 チッソ株式会社 蛍光活性を有するルシフェラーゼの活性増強方法
JP4761150B2 (ja) * 2006-07-24 2011-08-31 独立行政法人産業技術総合研究所 ハイスループット発光活性測定のためのセレンテラジン(ウミシイタケルシフェリン)溶液の安定化組成物および安定化法
US7718389B2 (en) * 2006-07-24 2010-05-18 National Institute Of Advanced Industrial Science And Technology Stabilizing composition and stabilizing method of coelenterazine solution for high-throughput measurement of luciferase activity
EP3141905B1 (en) * 2008-03-27 2019-03-06 Promega Corporation Protein labeling with cyanobenzothiazole conjugates
SG10202103336SA (en) * 2010-11-02 2021-04-29 Promega Corp Novel coelenterazine substrates and methods of use

Also Published As

Publication number Publication date
CN106661028A (zh) 2017-05-10
CN106661028B (zh) 2021-08-06
KR20170012271A (ko) 2017-02-02
JP2017519977A (ja) 2017-07-20
BR112016027504A2 (enExample) 2017-08-15
US20150337198A1 (en) 2015-11-26
AU2015263901B2 (en) 2021-03-11
EP3146066A1 (en) 2017-03-29
CA2949447A1 (en) 2015-11-26
AU2015263901A1 (en) 2016-11-24
KR102456212B1 (ko) 2022-10-20
WO2015179864A1 (en) 2015-11-26
JP6641297B2 (ja) 2020-02-05
BR112016027504B1 (pt) 2023-04-18
US9676997B2 (en) 2017-06-13
EP3146066B1 (en) 2018-03-14
CA2949447C (en) 2022-10-04

Similar Documents

Publication Publication Date Title
IL278643B (en) Methods and preparations for immune modulation
IL259576A (en) Preparations and methods for immuno-oncology
GB2535253B (en) Compositions and methods
GB2546350B (en) Compositions and methods
IL249446A0 (en) Preparations and methods for production packaging
GB201718876D0 (en) Antithrombin-heparin compositions and methods
IL246879A0 (en) Preparations of Epilimod and methods of using them
IL247614A0 (en) Methods and preparations for changing the immune response
GB201417828D0 (en) New methods and compositions
IL252738A0 (en) Carrier molecule preparations and related methods
IL249226A0 (en) Methods and preparations for immune modulation
SG11201701402QA (en) Anti-tumor compositions and methods
PL3113774T3 (pl) Kompozycje grapiprantu i sposoby ich zastosowania
EP3097420A4 (en) Methods and compositions for immune dis-inhibition
SG11201609382WA (en) Compositions and methods for stabilizing luminogenic substrates
ZA201703123B (en) Combination long acting compositions and methods for hepatitis c
IL248513A0 (en) Preparations and methods for immunomodulation against lyst
GB201512996D0 (en) Compositions and methods
PT3160263T (pt) Composições para prevenção de infeções
EP3221366A4 (en) Polyaminomethylbenzyloxalamides and compositions and methods related thereto
GB201514413D0 (en) Compositions and methods
GB201402915D0 (en) Compositions and methods
IL249103A0 (en) Compositions and methods for stabilizing luminogenic substrates
IL256261B (en) Hide1 compositions and methods
GB201403212D0 (en) Compositions and methods